Consequences of the 1989 New York State Triplicate Benzodiazepine Prescription Regulations
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Comparison of psychoactive medication prescribing and Medicaid expenditures before (1987 through 1988) and after (1989 through 1990) institution of the New York State triplicate benzodiazepine regulations. DATA SOURCES: The National Prescription Audit (IMS America, Plymouth Meeting, Pa), New York State Medicaid, and Blue Cross/Blue Shield fo the Rochester (NY) Area. RESULTS: From 1988 to 1989, New York State benzodiazepine prescribing decreased by 44%, 60%, and 30% as assessed by IMS America, Medicaid, and Blue Cross/Blue Shield, respectively. Prescribing of the following alternative sedative-hypnotics increased in New York State compared with decreases nationally (IMS America data): meprobamate, +125% vs -9%; methyprylon, +84% vs -15%; ethchlorvynol, +29% vs -18%; butabarbital, +31% vs -15%; hydroxyzine, +15% vs -1.1%; and chloralhydrate, +136% vs -0.4%. Increased prescribing of alternatives was also seen in the Medicaid and Blue Cross/Blue Shield data. Medicaid benzodiazepine expenditures decreased 52% from 1988 to 1989 ($21.7 million to $10.4 million). Alternative sedative expenditures increased 115% ($3.9 million to $8.4 million). Total Medicaid psychoactive medication expenditures remained nearly constant ($46.7 million to $45.6 million). CONCLUSION: Although the triplicate regulations have decreased benzodiazepine prescribing, an undesirable increase has occurred in the prescribing of less acceptable medications. The wider public health, patient care, and financial implications of triplicate benzodiazepine regulations are of concern and require further study before other jurisdictions undertake similar programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Opioid therapy for chronic nonmalignant pain: a review of the critical issues
Portenoy, R. K. (1996) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(95)00187-5 · Cited by 533
Pincus, H. A., Tanielian, T. L., Marcus, S. C., Olfson, M., Zarin, D. A., Thompson, J., & Zito, J. M. (1998) · JAMA · doi:10.1001/jama.279.7.526 · Cited by 423
A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes
Avorn, J., Soumerai, S. B., Everitt, D. E., Ross-Degnan, D., Beers, M. H., Sherman, D., Salem-Schatz, S. R., & Fields, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207163270306 · Cited by 397
Prescription Drug Monitoring Programs and Death Rates from Drug Overdose
Paulozzi, L. J., Kilbourne, E. M., & Desai, H. A. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01062.x · Cited by 372
Classics in Chemical Neuroscience: Diazepam (Valium)
Calcaterra, N. E., & Barrow, J. C. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5000056 · Cited by 281
Metadata
- Authors
- Weintraub, M.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1991-11-06
- Volume
- 266
- Issue
- 17
- Pages
- 2392
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2047523137
- Cited by
- 147
- References
- 0
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consequences of the 1989 New York State Triplicate Benzodiazepine Prescription Regulations. https://app.cochat.ai/papers/10.1001/jama.1991.03470170080028
- The paper
- Weintraub, M. (1991). Consequences of the 1989 New York State Triplicate Benzodiazepine Prescription Regulations. JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1991.03470170080028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.